-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Again, the "1 plus X" drug use model, which is dominated by essential drugs,opinion paper specifically proposes to optimize the list of antimicrobial supplyMedical institutions should optimize the supply of antimicrobialdrugs in conjunction with the "1 plus X" drug use model, which is dominated by essential drugs ("1" is the national list of essential drugs and "X" is non-essential drugs)More clearly than the current approach, the development of a catalogue of antimicrobial drug supply and prescription sets, in addition to the prescribed guarantee of the number of species, the selection of similar drugs should be selected in a safe, effective, economical and evidence-based varietiescountries have always stressed the need to establish a "1 plus X" drug use model dominated by essential drugs in public hospitals at all levelslast October, the General Office of the State Council issued "On further doing a good job in the work of supply and stability of drugs in short supply" (State Office issued (2019) No47) provisions: the number of basic drugs equipped with varieties of the proportion, according to the grass-roots, secondary and tertiary medical institutions are required not less than 90%, 80%, 60%, respectivelyin February this year, the National Health and Health Commission and six departments formulated the "Opinion on Strengthening the Management of PharmaceuticalS in Medical Institutions to Promote Rational Drug Use", which has clearly dynamically adjusted the national list of essential drugs, promoted medical institutions at all levels to form a "1 plus X" drug use model led by essential drugs, and improved the drug procurement systemIn this opinion draft, "1 plus X" has once again been highlightedthe second and third level hospital assessment: the basic drug into the important assessment indicators
the National Health and Health Commission Office published "on the collection of second- and third-level public hospitals in 2019 annual performance appraisal data related to the work of the notice", marking the second and third-level public hospital performance appraisal data collection is about to startin the performance appraisal system of second- and third-level hospitals, the use of essential drugs has become an important assessment indexAmong them, the three-level hospitals related to the basic drug assessment indicators are: outpatientprescription ratio, inpatient systomic drug utilization rate, basic drug procurement of the number of varieties accounted for three, secondary hospitals in the basic drug assessment indicators for the proportion of basic drugs procurement amountthe performance appraisal target of the second and third level hospitals will greatly strengthen the execution of medical personnel because of the linkage with salary promotion and so onThe Notice makes it clear that it is strictly prohibited to fabricate, falsely report or conceal data, and that units and individuals that have deliberately fabricated, misrepresented, concealed data and other violations of discipline in the course of the examination will be dealt with seriously-based medicine is limited to common generics?early primary drug use, mainly for the use of primary medical institutions, to commonly used general drug species, this kind of thinking has not been suitable for the graded diagnosis and treatment of the general environment Medical insurance catalog, base medicine catalog dynamic adjustment needs, consistency evaluation of the varieties, major disease innovation drugs, the efficacy of clear traditional Chinese medicine, may become the potential varieties of the base drug The base drug catalogue, while meeting primary drug use, covers more diseases, and the tendency to meet the drug use of all medical institutions is very obvious the base drug catalog shuffle as a policy main line of the basic drug policy, under the strong promotion of the National Health and Health Commission, strengthen the management of the use of base drugs equipped with the clinical port to eliminate non-base drug species, there have been local, hospitals have taken positive measures, not only to vigorously improve the proportion of base drug use, and even hospitals directly introduced non-base drug removal catalog April, jiangmen City, Guangdong Province, the New Club District People's Hospital issued a notice that because the first quarter of 2020 the base drug equipped with 43.14 percent of the varieties, the use of the amount of 35.7 percent, are not up to standard by the New Council health and health bureau for interviews May, Shandong Provincial Health and Health Commission issued a notice, starting from May 2020, divided into four stages of the formulation of programs, start implementation, effectiveness assessment, summary and promotion of the implementation of the national basic drug system comprehensive pilot, requiring medical institutions at all levels to fully equip and priority use of basic drugs, the formation of a base drug-led "1 plus x" drug use model June, Shenzhen Central Hospital announced the "2020 phase-out of non-national basic drug varieties directory", a total of 148 varieties, including amoxicillin kraviate (7:1) dispersion tablets, human haemoglobin, Changchun sitin injection, injection with safan yellow, injection with brain protein hydrolysis and many other well-known varieties series of policies from 2019 to the present shows that the country has a clear drug-oriented approach to clinical drug use, that is, the drug-based drug structure as the core, the formation of base drugs, medical insurance drugs (the amount of procurement of drugs, varieties of state-to-state), the evaluation of the variety of drug "priority." the price of base drugs is generally low, there are some objective challenges in marketing and marketing With the clear structure of the drug with the base drug as the core, and the implementation of the proportion of base drug use, the dynamic adjustment of the base drug catalog has become a must-have place for pharmaceutical companies Entering the base medicine catalog means saving the cost of admission to and upto, which will bring new opportunities and tests to the enterprise.